Establish manufacturing capabilities for variant vaccines in the UK
Deadline passed; outcome being checked
- Announced
- 5 Feb 2021
- Due
- 5 Feb 2024
- Status
- Checking
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“manufacturing capabilities will be in place for rapid production of large quantities of variant vaccines for the UK if and when needed over the next three years”
What we found
The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Facility other
- Indicative materiality
- Medium rules
- Action
- Establish
- Deliverable
- manufacturing capabilities for variant vaccines
- Where
- UK
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: subject to regulatory approval
- Depends on
- Regulatory, Partner
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you CureVac N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C809122-023189 · Corrections policy